Emerging Stocks Down Under 3 May 2022: Kazia Therapeutics (ASX:KZA)
Kazia Therapeutics: A biotech taking on brain cancerKazia Therapeutics is tackling brain cancer, which is one of the deadliest forms of cancer. It's lead asset Paxalisib has passed a Phase 2 and is currently in a Phase 3 study along with additional Phase 1 studies against other indications. We like this company for its cash reserves, the strong IP protection of its assets along with the work it has done to prepare for the drug's eventual commercialisation. Click here to read the previous edition of Emerging Stocks Down Under published 26 April 2022 For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.
Please register or upgrade your plan to access this content.